Bachem: Overcoming Pharmaceutical Supply Chain Hurdles
The global pharmaceutical supply chain has encountered numerous disruptions in recent times, from geopolitical upheaval to environmental disasters. These disruptions underscore a critical need for the industry to adopt robust strategies to ensure the continuous delivery of essential medications worldwide.
Since the early 2000s, global crises like the 2008 financial downturn, COVID-19 pandemic and ongoing conflict in Ukraine have revealed significant vulnerabilities in pharma supply chains. These events have challenged the industry to improve their operational resilience.
"Pharmaceutical supply chains are becoming increasingly vulnerable to a range of disruptions," explains Pascal Degen, Vice President of Global Supply Chain Management at Bachem. "The unpredictability of the modern world demands innovative strategies for maintaining stability in the face of disruption."
The effect of such disruptions is profound. For instance, between late 2020 and early 2022, 255 clinical trials were recorded in Ukraine. But post-conflict, from mid-2022 to mid-2023, the count drastically fell to just 33—an 87% decrease, illustrating how regional conflicts can affect global pharmaceutical operations.
Challenges Facing CDMOs
Pharmaceutical manufacturing demands the management of vast, complex supply chains.
Contract development and manufacturing organisations (CDMOs) – responsible for ensuring regulatory compliance, operational efficiency and consistent product quality – face substantial obstacles in maintaining smooth operations.
"CDMOs play a critical role in navigating challenges by ensuring the consistent production and delivery of life-saving medications," Pascal notes. "There is a pressing need for CDMOs to address supply chain challenges in a volatile, uncertain, complex and ambiguous (VUCA) environment."
Major challenges include navigating diverse international regulatory requirements, reducing over-dependence on specific geographic areas for raw materials and overcoming traditional batch manufacturing limitations.
The COVID-19 pandemic showcased these vulnerabilities starkly, with the US experiencing 143 shortages of different anaesthesia medications in 2020.
Four cornerstones of resilience
According to Pascal, building a reliable supply chain resilience framework involves four key elements:
Visibility: Pascal points out that real-time supply chain monitoring "ensures early detection of potential disruptions," which helps in taking swift actions to minimise effects downstream. This visibility fosters proactive management rather than reactive responses and lets leaders anticipate problems before they expand.
Flexibility: In an unpredictable environment, adaptability is vital. "Adapting strategies, such as sourcing from a broader base of suppliers and scalable manufacturing processes, helps CDMOs effectively respond to changes," Pascal asserts. This flexibility decreases reliance on single-source suppliers and eases supply bottlenecks.
Collaboration: Building resilience can’t be isolated to a single company. "Collaborative efforts among suppliers, manufacturers and logistics providers help the entire supply chain manage disruptions more efficiently," he stresses, adding that strong partnerships foster mutual trust and commitment.
Control and transparency: Governance and clear communication also play a crucial role. "Transparent operations align with stakeholder expectations and reduce risks, maintaining compliance," Pascal explains.
Technology’s role in enhancing resilience
Innovation is fundamentally altering the landscape of pharmaceutical supply chains, introducing new tools that bolster resilience.
"Innovative technologies are playing a pivotal role in reinforcing pharmaceutical supply chains," Pascal notes.
He highlights that tools such as predictive analytics and blockchain are crucial for improving traceability and operational decisions.
Technological advancements are slowly but certainly transforming the sector. Continuous processing technologies, for example, offer more efficiency and scalability compared to traditional batch processes, decreasing vulnerabilities.
Strategising for future challenges
Pascal outlines several strategies for pharmaceutical companies to survive in an increasingly unpredictable environment.
"The pharmaceutical industry must adapt to a world where disruption is the norm," he adds.
This adaptation involves diversifying supply sources, strengthening partnerships, leveraging technology and enhancing system agility.
As disruptions continue to intensify, particularly for CDMOs, prioritising supply chain resilience becomes crucial to ensure the uninterrupted delivery of critical medications and safeguard patient safety globally.
"CDMOs must lead the charge by adopting comprehensive, forward-thinking strategies that address the complexities of a globalised industry," Pascal concludes.
By embracing visibility, flexibility, collaboration and transparency, organisations like Bachem are positioning themselves to withstand future challenges, ultimately ensuring the health and safety of patients worldwide.
Explore the latest edition of Supply Chain Digital and be part of the conversation at our global conference series, Procurement & Supply Chain LIVE.
Discover all our upcoming events and secure your tickets today.
Supply Chain Digital is a BizClik brand.